Advertisement
Canada markets closed
  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • Bitcoin CAD

    82,862.73
    -2,611.84 (-3.06%)
     
  • CMC Crypto 200

    1,302.78
    -55.23 (-4.07%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     
  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     
  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     
  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     

Stocks fight back as Netflix pares losses

Stocks are rebounding as Netflix pares losses and the Nasdaq pushes to another new high. Plus, do Netflix’s slowing subscriber numbers signal bad things to come?

And Prime Day still going on strong despite site issues. We have the latest. Plus, Lee Munson is here and explains why he’s looking at emerging markets, and the beaten down banks for a trade. Catch The Final Round at 3:55 ET p.m. with Jen Rogers, Yahoo Finance markets correspondent Myles Udland, and reporter Dan Roberts.

Winners and losers

Stocks in the red include Redfin as the real-estate brokerage site announced a secondary offering of 3.5 million shares, and $125 million worth of convertible notes, Omnicon as the marketing and media buying firm’s revenue growth in the second quarter fell short of expectations, and UnitedHealthcare — the insurer and Dow component is sliding despite an earnings beat, as analysts expected a bigger beat and are concerned about medical cost trends.

Stocks in the green include International Game Technology as the gaming and slot machine company struck a deal to provide FanDuel its sports betting platform, Cellectar Biosciences surging after a patient in a cancer drug trial for Non-Hodgkin’s lymphoma had a 94% reduction in a tumor, and Johnson & Johnson as the health company beat on revenue and earnings as its pharmaceutical business fueled the company’s Q2 growth.